The Use of Early and Midpoint Adenoma-Carcinoma Sequence Biomarkers in Prediction of Neoplastic Progression in Patients with a History of Colorectal Neoplasia

详细信息    查看全文

• 作者：Hassan Albataineh ; Violeta Yordanova ; Jessica Bowman ; WeiLi Zhou ; James Hatfield ; Michael J. Lawson ; Paula Sochacki and Martin Tobi
• 关键词：Deleted in colon cancer ; Adnab ; 9 ; Monoclonal antibodies ; Colonic effluent
• 刊名：Digestive Diseases and Sciences
• 出版年：2006
• 出版时间：December, 2006
• 年：2006
• 卷：51
• 期：12
• 页码：2213-2219
• 全文大小：316 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Hepatology
  Oncology
  Transplant Surgery
  Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-2568

文摘

Since significant neoplasia after initial colonoscopy is low, we conducted this pilot study to compare the predictive role for colorectal neoplasia recurrence of anti-DCC with that of Adnab-9 binding to colonic effluent of high-risk patients. DCC and Adnab-9 effluent ELISA were performed at baseline colonoscopies. The results of follow-up colonoscopies were reviewed. To ensure specificity, immunohistochemistry and Western blot was performed with anti-DCC and for Adnab-9 where optimal fixation times were also evaluated. Mean follow-up was 2.6 years. Of 21 patients, 6 of 10 who progressed to CRN and 2 of 11 who did not had a positive Adnab-9 ELISA result (P=0.08). Despite an initial good correlation with Adnab-9 ELISA results in a smaller dataset, we were unable to obtain consistent subsequent DCC immunohistochemistry or Western blot data using antibody from two different sources. However, the original dataset of Adnab-9 results was reproducible on repetition of the ELISA with a larger set of samples that included this initial dataset and optimal fixation time was 20 min. We conclude that Adnab-9 appears to be a promising prognostic marker for neoplasia in the high-risk population. Industry standards need to be developed for DCC monoclonal antibodies that may have similar utility.